Avacta Group said a research collaboration with Finland's FIT Biotech had produced 'very encouraging' data relating to its biotherapeutics and reagents.

The proof-of-concept study showed sustained production of the company's Affimer molecules by the muscle tissue of mice.

This was achieved from a single dosing of the Affimer DNA using FIT technology.

'The potential commercial and patient benefits of achieving sustained production of Affimer therapeutics by the body through delivery of just the Affimer DNA are vast, and it is very exciting to see such encouraging results of this exploratory study' chief executive Alastair Smith said.

'From this initial data, the combination of the two companies' technologies appears to be very effective and we will now explore the different opportunities to take this forward collaboratively, and with larger partners.'




At 2:36pm: (LON:AVCT) Avacta Group PLC share price was +6p at 35.5p